Abstract
Angiostatins, kringle-containing fragments of plasminogen, are potent inhibitors of angiogenesis. Effects of three angiostatin forms, K1–3, K1–4, and K1-4.5 (0–2 µM), on the rate of native Glu-plasminogen activation by its physiological activators in the absence or presence of soluble fibrin were investigated in vitro. Angiostatins did not affect the intrinsic amidolytic activities of plasmin and plasminogen activators of tissue type (tPA) and urokinase type (single-chain scuPA and two-chain tcuPA), but inhibited conversion of plasminogen to plasmin in a dose-dependent manner. All three angiostatins suppressed Glu-plasminogen activation by tcuPA independently of the presence of fibrin, and the inhibitory effect increased in the order: K1-3 < K1-4 < K1-4.5. The inhibitory effects of angiostatins on the scuPA activator activity were lower and further decreased in the presence of fibrin. Angiostatin K1-3 (up to 2 µM) had no effect, while 2 µM angiostatins K1-4 and K1-4.5 inhibited the fibrin-stimulated Glu-plasminogen activation by tPA by 50 and 100%, respectively. The difference in effects of the three angiostatins on the Glu-plasminogen activation by scuPA, tcuPA, and tPA in the absence or presence of fibrin is due to the differences in angiostatin structures, mechanisms of action, and fibrin-specificity of plasminogen activators, as well as due to the influence of fibrin on the Glu-plasminogen conformation. Angiostatins in vivo, which mimic plasminogen-binding activity, can inhibit plasminogen activation stimulated by various proteins (including fibrin) of extracellular matrix, thereby blocking cell migration and angiogenesis. The data of this work indicate that the inhibition of Glu-plasminogen activation under the action of physiological plasminogen activators by angiostatins can be implicated in the complex mechanism of their antiangiogenic and antitumor action.
Similar content being viewed by others
Abbreviations
- AFK-pNA:
-
HCO-Ala-Phe-Lys p-nitroanilide
- 6-AHA:
-
6-aminohexanoic acid
- α2-AP:
-
α2-antiplasmin
- Glu-Pg and Lys-Pg:
-
Glu- and Lys-form of plasminogen, respectively
- LBS:
-
lysine-binding center
- MMPs:
-
matrix metal proteinases
- NTP:
-
NH2-terminal peptide
- PA(s):
-
plasminogen activator(s)
- PAI-1:
-
plasminogen activator inhibitor-1
- Pm:
-
plasmin
- scuPA:
-
single-chain urokinase-type plasminogen activator (pro-urokinase)
- tcuPA:
-
two-chain urokinase-type plasminogen activator (urokinase)
- tPA:
-
tissue-type plasminogen activator
- SK:
-
streptokinase
- S-2444:
-
Glp-Gly-Arg p-nitroanilide
- S-2288:
-
H,D-Ile-Pro-Arg p-nitroanilide
References
Dvorak, H. F. (2005) J. Thromb. Haemost., 3, 1835–1842.
Staton, K. A., and Lewis, C. E. (2005) J. Cell. Mol. Med., 9, 286–302.
Romer, J. (2003) APMIS, Suppl. 107, 111, 1–36.
Egeblat, M., and Werb, Z. (2002) Nat. Rev. Cancer, 2, 161–173.
Ploug, M. (2003) Curr. Pharm. Des., 9, 1499–1528.
Dano, K., Behrendt, N., Hoyer-Hansen, G., Johnsen, M., Lund, L. R., Ploug, M., and Romer, J. (2005) Thromb. Haemost., 93, 676–681.
Almholt, K., Lund, L. R., Rygaard, J., Nielsen, B. S., Dano, K., Romer, J., and Johnsen, M. (2005) Int. J. Cancer, 113, 525–532.
Collen, D., and Lijnen, H. R. (2005) Thromb. Haemost., 93, 627–630.
Melchor, J. P., and Strickland, S. (2005) Thromb. Haemost., 93, 655–660.
Burtin, P., Chavanel, G., and Andre, J. (1985) Int. J. Cancer, 35, 307–314.
Clavel, C., Chavanel, G., and Birembaut, P. (1986) Cancer Res., 46, 5743–5747.
Burtin, P., Chavanel, G., Andre-Bougaran, J., and Gentile, A. (1987) Int. J. Cancer, 39, 170–178.
Wallen, P., and Wiman, B. (1970) Biochim. Biophys. Acta, 221, 20–30.
Sottrup-Jensen, L., Claeys, H., Zajdel, M., Petersen, T. E., and Magnusson, S. (1978) Prog. Chem. Fibrinol. Thromb., 3, 191–209.
Robbins, K. C., Summaria, L., Hsieh, B., and Shah, R. J. (1967) J. Biol. Chem., 242, 2333–2342.
Marcus, G., de Pascuale, J. L., and Wissler, F. C. (1978) J. Biol. Chem., 253, 727–732.
Wiman, B., Lijnen, H. R., and Collen, D. (1979) Biochim. Biophys. Acta, 579, 142–154.
Dudani, A. K., Ben-Tchavtchavadze, M., Porter, S., and Tackaberry, E. (2005) Biochem. Cell Biol., 83, 28–35.
Felez, J., Miles, L. A., Fabregas, P., Jardi, M., Plow, E. F., and Lijnen, H. R. (1996) Thromb. Haemost., 76, 577–584.
Stack, M. S., Gately, S., Bafetti, L. M., Enghild, J. J., and Soff, G. A. (1999) Biochem. J., 340, 77–84.
O’Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. (1994) Cell, 79, 315–328.
Kwon, M., and Waisman, D. M. (2003) in Plasminogen: Structure, Activation and Regulation (Waisman, D. M., ed.) Kluwer Academic/Plenum Publishers, New York, pp. 135–156.
Cao, Y., Ji, R. W., Davidson, D., Schaller, J., Marti, D., Sohndel, S., McCance, S. G., O’Reilly, M. S., Llinas, M., and Folkman, J. (1996) J. Biol. Chem., 271, 29461–29467.
MacDonald, N. J., Murad, A. C., Fogler, W. E., Lu, Y., and Sim, B. K. L. (1999) Biochem. Biophys. Res. Commun., 264, 469–477.
Cao, R., Wu, H. L., Veitonmaki, N., Linden, P., Farnebo, J., Shi, C. Y., and Cao, Y. (1999) Proc. Natl. Acad. Sci. USA, 96, 5728–5733.
Chen, Y.-H., Wu, H.-L., Li, C., Huang, Y.-H., Chiang, C.-W., Wu, M.-P., and Wu, L.-W. (2006) Thromb. Haemost., 95, 668–677.
Levashov, M. Yu., Aisina, R. B., Gershkovich, K. B., and Varfolomeyev, S. D. (2007) Biochemistry (Moscow), 72, 707–715.
Powell, J. R., and Castellino, F. J. (1980) J. Biol. Chem., 255, 5329–5335.
Laemmli, U. K. (1970) Nature, 227, 680–685.
Aisina, R., Mukhametova, L., Gershkovich, K., and Varfolomeyev, S. D. (2005) Biochim. Biophys. Acta, 1725, 370–376.
Kassam, G., Kwon, M., Yoon, C.-S., Graham, K. S., Young, M. K., Gluck, S., and Waisman, D. M. (2001) J. Biol. Chem., 276, 8924–8933.
Hoylaerts, M., Rijken, D. C., Lijnen, H. R., and Collen, D. (1982) J. Biol. Chem., 257, 2912–2919.
Wang, H., Doll, J. A., Jiang, K., Cundiff, D. L., Czarnecki, J. S., Wilson, M., Ridge, K. M., and Soff, G. A. (2006) Cancer Res., 66, 7211–7215.
Wu, H.-L., Chang, B.-I., Wu, D.-H., Chang, L.-C., Gong, C.-C., Lou, K.-L., and Shi, G.-Y. (1990) J. Biol. Chem., 265, 19658–19664.
Cao, Y. (1999) Haematologica, 84, 643–650.
Castellino, F. J. (1984) Semin. Thromb. Haemost., 10, 18–23.
Sim, B. K., O’Reilly, M. S., Liang, H., Fortier, A. H., He, W., Madsen, J. W., Lapcevich, R., and Nacy, C. A. (1997) Cancer Res., 57, 1329–1334.
Ponting, C. P., Marshall, J. M., and Cederholm-Williams, S. A. (1992) Blood Coagul. Fibrinol., 3, 605–614.
Boxtrud, P. D., and Bock, P. E. (2000) Biochemistry, 39, 13974–13981.
Cockell, C. S., Marshall, J. M., Dawson, K. M., Cederholm-Williams, S. A., and Ponting, C. P. (1998) Biochem. J., 333, 99–105.
Binder, B. R. (1995) Fibrinolysis, 9(Suppl. 1), 3–8.
Bachmann, F. (1995) Fibrinolysis, 9(Suppl. 1), 9–15.
Fears, R., Hibbs, M. J., and Smith, R. A. G. (1985) Biochem. J., 229, 555–558.
Lijnen, H. R., Stump, M. D., and Collen, D. C. (1987) Semin. Thromb. Haemost., 13, 152–159.
Gurewich, V. (2001) in Fibrinolytics and Antifibrinolytics (Bachmann, F., ed.) Springer-Verlag, Berlin, pp. 231–260.
Mogues, T., Etzerodt, M., Hall, C., Engelich, G., Graversen, J. H., and Hartshorn, K. L. (2004) J. Biomed. Biotechnol., 2, 73–78.
Castellino, F. J., and Ploplis, V. A. (2005) Thromb. Haemost., 93, 647–654.
Stillfried, G. E., Saunders, D. N., and Ranson, M. (2007) Breast Cancer Res., 9, R14 (online version is available on the site http://breast-cancer-research.com/content/9/1/R14).
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © R. B. Aisina, L. I. Mukhametova, D. A. Gulin, M. Y. Levashov, N. V. Prisyazhnaya, K. B. Gershkovich, S. D. Varfolomeyev, 2009, published in Biokhimiya, 2009, Vol. 74, No. 10, pp. 1356–1367.
Rights and permissions
About this article
Cite this article
Aisina, R.B., Mukhametova, L.I., Gulin, D.A. et al. Inhibitory effect of angiostatins on activity of the plasminogen/plasminogen activator system. Biochemistry Moscow 74, 1104–1113 (2009). https://doi.org/10.1134/S000629790910006X
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S000629790910006X